Q32 Bio Inc. (QTTB)

NASDAQ: QTTB · IEX Real-Time Price · USD
17.04
+0.87 (5.38%)
At close: Mar 28, 2024, 4:00 PM
16.70
-0.34 (-2.00%)
After-hours: Mar 28, 2024, 5:24 PM EDT

Company Description

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States.

The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders.

Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies.

Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Q32 Bio Inc.
Q32 Bio logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Arthur Tzianabos

Contact Details

Address:
One Patriots Park
Bedford, Massachusetts 01730
United States
Phone 781-301-7277

Stock Details

Ticker Symbol QTTB
Exchange NASDAQ
Fiscal Year January - December
CIK Code 0001661998
CUSIP Number 438083107
ISIN Number US4380831077
Employer ID 47-3468154
SIC Code 2834

Key Executives

Name Position
Dr. Paul Alloway J.D., Ph.D. President and Chief Operating Officer
Dr. Saswati Chatterjee Ph.D. Co-Founder and Member of Scientific Advisory Board
Charles Michaud Jr., CPA Vice President of Finance, Corporate Controller and Treasurer
Theresa McNeely Chief Communications Officer and Patient Advocate

Latest SEC Filings

Date Type Title
Mar 28, 2024 SC 13D General statement of acquisition of beneficial ownership
Mar 27, 2024 8-K Current Report
Mar 22, 2024 8-K/A [Amend] Current report
Mar 20, 2024 8-K Current Report
Mar 15, 2024 8-K Current Report
Mar 14, 2024 SCHEDULE 13G Filing
Mar 13, 2024 POS EX Filing
Mar 13, 2024 424B3 Prospectus
Mar 13, 2024 10-K Annual Report
Mar 11, 2024 425 Filing